Frank E. Thomas
Net Worth

Last updated:

What is Frank E. Thomas net worth?

The estimated net worth of Mr. Frank E. Thomas is at least $2,930,900 as of 10 Mar 2023. He has received compensation worth at least $2,930,900 in Orchard Therapeutics plc.

What is the salary of Frank E. Thomas?

Mr. Frank E. Thomas salary is $586,180 per year as Pres & Chief Operating Officer in Orchard Therapeutics plc.

How old is Frank E. Thomas?

Mr. Frank E. Thomas is 55 years old, born in 1970.

What stocks does Frank E. Thomas currently own?

As insider, Mr. Frank E. Thomas owns shares in one company:

Company Title Shares Price per share Total value
Orchard Therapeutics plc (ORTX) Pres & Chief Operating Officer 52,081 $0 $0

What does Orchard Therapeutics plc do?

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Frank E. Thomas insider trading

Orchard Therapeutics plc

Transaction Date Security Shares Price per share Total value Source
Option
Stock Option (Right to Buy) 20,000 $0.46 $9,180
Option
Ordinary Shares 20,000 $0.46 $9,180
Option
Stock Option (Right to Buy) 20,000 $0.46 $9,180
Option
Ordinary Shares 20,000 $0.46 $9,180
Purchase
Ordinary Shares 10,000 $0.75 $7,470
Option
Ordinary Shares 10,000 N/A N/A
Option
Stock Option (Right to Buy) 10,000 N/A N/A
Option
Stock Option (Right to Buy) 10,000 N/A N/A
Option
Ordinary Shares 10,000 N/A N/A

Orchard Therapeutics key executives

Orchard Therapeutics plc executives and other stock owners filed with the SEC: